Orthopediatrics KIDS
- Market cap
- $639.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $252.7M
- +14% on a year ago
- Net margin
- −15.7%
- Free cash flow yield
- −0.3%
Orthopediatrics trades at 2.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $252.7M over the last twelve months, up 14% on a year earlier with a −16% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $40M+14% | $37.6M+21% | $44.7M+42% | $52.8M+34% | $54.6M+37% | $52.7M+40% | $52.4M+17% | $61.1M+16% | $61.3M+12% | $61.6M+17% | $59.4M+13% | $70.5M+15% | |
| Cost of revenue | $9M−1% | $10.9M+12% | $12.5M+56% | $12M+26% | $14.5M+61% | $17.1M+57% | $14.1M+13% | $17.1M+42% | $16M+10% | $16.5M−4% | $16M+13% | $18.1M+6% |
| Gross profit | $31M+20% | $26.7M+26% | $32.2M+37% | $40.8M+36% | $40.1M+29% | $35.6M+33% | $38.3M+19% | $44M+8% | $45.3M+13% | $45.1M+27% | $43.4M+13% | $52.4M+19% |
| R&D | $2.6M+16% | $2.9M+44% | $3M+23% | $2.5M−14% | $2.6M+1% | $2.9M−0% | $2.4M−22% | $2.2M−15% | $2.3M−10% | $2.3M−23% | $2.2M−5% | $2.3M+8% |
| SG&A | $31.9M+18% | $31.9M+16% | $38.9M+31% | $43.9M+35% | $43M+35% | $41.2M+29% | $46.9M+20% | $49.5M+13% | $47.8M+11% | $48.4M+17% | $49.5M+6% | $54.1M+9% |
| −$4.5M−35% | −$8.1M−3% | −$9.7M+13% | −$5.7M+1% | −$5.6M+24% | −$14.1M+74% | −$11M+13% | −$10.7M+88% | −$9.4M+69% | −$8.2M−42% | −$8.3M−24% | −$4.1M−62% | |
| Interest expense | $21K−97% | −$63K+3% | $637K+5691% | $261K−11% | $404K+1824% | $1.3M | $1.1M+77% | $1.1M+328% | $1.8M+351% | $1.9M+47% | $2.1M+87% | $2.5M+127% |
| Pre-tax income | −$3.7M | −$6.9M−13% | −$10.3M+40% | −$6M+84% | −$9.1M+144% | −$16.4M+138% | −$10.5M+1% | −$7.1M+17% | −$11.9M+30% | −$9.8M−41% | −$10.9M+4% | −$6.9M−2% |
| $849K | −$212K+342% | −$2.5M+341% | −$18K−96% | −$1.2M | −$340K+60% | $196K | $49K | −$125K−90% | $340K | −$171K | $234K+378% | |
| Net income | −$4.6M | −$6.7M−15% | −$7.8M+15% | −$6M+109% | −$7.9M+73% | −$16.1M+140% | −$10.7M+37% | −$7.1M+18% | −$11.8M+49% | −$10.1M−37% | −$10.7M+0% | −$7.2M+1% |
| −$0.20 | −$0.29−22% | −$0.34+13% | −$0.26+100% | −$0.34+70% | −$0.69+138% | −$0.46+35% | −$0.30+15% | −$0.50+47% | −$0.43−38% | −$0.45−2% | −$0.30+0% | |
| 22.8M+7% | 22.8M+10% | 22.8M+1% | 23.1M+2% | 23.2M+2% | 23.2M+2% | 23.2M+2% | 23.5M+1% | 23.6M+2% | 23.6M+2% | 23.7M+2% | 24M+3% |
Net income: 4 periods, Q2 FY19 to Q2 FY20: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY16 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 9 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Orthopediatrics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KIDSOrthopediatrics | $639.7M | n/m | 234× | 2.5× | +14% | −15.7% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| CDRECadre | $1.3B | 37.0× | 35.8× | 1.9× | +20% | 5.3% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| EYENational Vision | $1.5B | 30.6× | 53.3× | 0.7× | +8% | 2.5% | |
| Peer median | $899.7M | 32.3× | 38.6× | 1.7× | +7% | 6.0% |
More on Orthopediatrics
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .